Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma

Inclusion Criteria: * Must be 18 to 75 years of age. * ECOG performance status of 0, 1 or 2. * Patients who have a history of another malignant disorder are eligible, provided that they have not received active therapy for 5 years. Patients with basal cell and squamous cell skin cancers are eligible. * Patients who are pregnant are ineligible. * Patients must furnish written informed consent and HIPAA authorization for release of personal health information. * Patients must be able to understand the requirements of the study, abide by the study restrictions, and agree to return for the required assessments. * Patients must be HIV and HTLV-I,-II antibody sero-negative. * Patients must have adequate visceral organ function Exclusion Criteria: * Patients are ineligible if they have received cumulative chemotherapy doses in excess of: carmustine (BCNU) 400 mg/m2, or a cumulative anthracycline exposure in excess of 550 mg/m2 Adriamycin (doxorubicin) unless the gated-pool radionuclide cardiac scan shows greater than/equal to 45% ejection fraction. * Patients are ineligible if they are receiving any other investigational agents.